Is hormone replacement therapy-related breast cancer more favorable? A case-control study

Breast Journal

Volumn 13, Issue 5, 2007, Pages 496-500

  Khan, Hamed N ^a,b   Bendall, Susan ^a   Bates, Tom ^a  

^a WILLIAM HARVEY HOSPITAL   (United Kingdom)

^b General Surgery   (United Kingdom)

Author keywords

Breast cancer; Hormone replacement therapy; Prognosis; Survival

Indexed keywords

ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER MORTALITY; CANCER SURVIVAL; CASE CONTROL STUDY; CAUSAL ATTRIBUTION; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; PROGNOSIS; RISK FACTOR; TUMOR VOLUME;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS;

EID: 34548207594     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2007.00471.x     Document Type: Article

References (17)

1. Nerhood RC. Making a decision about ERT/HRT. Evidence to consider in initiating and continuing protective therapy. Postgrad Med 2001 109 : 167 70.
2. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 without breast cancers. Lancet 1997 350 : 1047 59.
3. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: oestrogen versus oestrogen plus progestin. J Natl Cancer Inst 2000 92 : 328 32.
4. Levi F, Lucchini F, Pasche C, La Vecchia C. Oral contraceptives, menopausal hormone replacement treatment and breast cancer. Eur J Cancer Prev 1996 5 : 259 66.
5. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with a favourable histology: results of the Iowa Women's Health Study. JAMA 1999 281 : 2091 97.
6. Jernstorm H, Fernander J, Ferno M, Olsson H. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 1999 80 : 1453 58.
7. Balslev L, Axelson CK, Zedelev K, et al. The Nottingham Prognostic Index applied to 9149 patients from the studies of the Danish Breast Cancer Co-operative Group (DBCG). Breast Cancer Res Treat 1994 32 : 281 90.
8. Pinder SE, Elston CW, Ellis IO. Prognostic factors and management of primary breast cancer. Adv Clin Path 1997 1 : 5 12.
9. Galea MH, Blamey RW, Elston CW, Ellis IO. The Nottingham Prognostic Index. Breast Cancer Res Treat 1992 22 : 207 19.
10. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002 288 : 321 33.
11. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003 362 : 419 27.
12. Manjer J, Malina J, Berglund G, Bondeson L, Garne JP, Janzon L. Increased incidence of small and well differentiated breast tumours in postmenopausal women following hormone-replacement therapy. Int J Cancer 2001 92 : 919 22.
13. Harding C, Knox WF, Faragher EB, Baildam A, Bundred NJ. Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. BMJ 1996 312 : 1646 47.
14. Stallard S, Litherland J, Cordiner C, et al. Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study. BMJ 2000 320 : 348 49.
15. Prasad R, Iddon J, Knox WF, et al. Use of hormonal replacement therapy (HRT) does not adversely affect survival. Eur J Cancer 2001 37 (Suppl. 5:0-99) : 34 35.
16. Banks E. Hormone replacement therapy and therapy and the sensitivity and specificity of breast cancer screening: a review. J Med Screen 2001 8 : 29 34.
17. Lundstrom E, Wilczek B, Von Palffy Z, Soderqvist G, Von Schoultz B. Mammographic breast density during hormone replacement therapy: effects of continuous combination, unopposed transdermal and low-potency estrogen regimens. Climacteric 2001 4 : 42 48.